サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：肺疾患治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測
市場調査レポート
商品コード
1346841

肺疾患治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測

Global Lung Disease Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日: | 発行: Value Market Research | ページ情報: 英文 242 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
肺疾患治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測
出版日: 2023年08月01日
発行: Value Market Research
ページ情報: 英文 242 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

肺疾患治療薬市場の世界需要は、調査期間2023年～2030年のCAGR4.7%で、2022年の804億1,000万米ドルから2030年にはほぼ1,164億1,000万米ドルの市場規模に達すると推定されます。

肺疾患治療薬とは、肺に関連する様々な疾患や疾病を管理・治療することを目的とした医学的治療や介入を指します。肺機能と呼吸器全体の健康に影響を及ぼす急性疾患と慢性疾患の両方を含む、呼吸器系に影響を及ぼす疾患が対象となります。これらの治療法には、薬物療法、治療法、生活習慣の改善、場合によっては外科的介入など、様々なアプローチが含まれます。

市場力学：

公害や高齢化などの要因による肺疾患の有病率の増加が、効果的な治療に対する需要を促進しています。環境要因、技術の進歩、研究が治療ニーズの高まりに寄与しています。個別化医療や標的治療薬などの新たなバイオ医薬品は、治療の選択肢を増やします。ヘルスケア支出の増加、早期診断の意識、規制基準の厳格化が重要な役割を果たしています。COVID-19パンデミックは、呼吸器衛生の重要性を浮き彫りにし、この分野の研究を加速させました。世界のイニシアティブ、ヘルスケアインフラの開拓、患者中心のアプローチはさらに市場に影響を与えます。患者やヘルスケア専門家が治療法の改善を求める中、市場は進化していくと予想されます。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を取り上げています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、肺疾患治療薬の世界市場における各セグメントを包括的に評価することもできます。肺疾患治療薬業界の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析：

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東＆アフリカにおける肺疾患治療薬市場の現在および将来の需要を強調する地域展望をカバーしています。さらに、すべての主要地域における個々の用途セグメントの需要、推定・予測にも焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 肺疾患治療薬- 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 肺疾患治療薬の世界市場分析：疾患タイプ別

  • 疾患タイプ別概要
  • 実績データと予測データ
  • 疾患タイプ別分析
  • 喘息
  • 慢性閉塞性肺疾患（COPD）
  • 肺がん
  • その他の肺疾患

第6章 肺疾患治療薬の世界市場分析：薬剤クラス別

  • 薬剤クラス別概要
  • 実績データと予測データ
  • 薬剤クラス別分析
  • 副腎皮質ステロイド薬
  • 気管支拡張薬
  • 粘液溶解薬
  • 抗菌薬
  • その他

第7章 肺疾患治療薬の世界市場分析：流通チャネル別

  • 流通チャネル別概要
  • 実績データと予測データ
  • 流通チャネル別分析
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 肺疾患治療薬の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東とアフリカ

第9章 肺疾患治療薬企業の競合情勢

  • 肺疾患治療薬市場の競合
  • 提携・協力・合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第10章 企業プロファイル

  • 企業シェア分析
  • 市場集中度
  • GSK
  • AstraZeneca
  • Boehringer Ingelheim
  • Novartis
  • Mylan
  • Vertex Pharmaceuticals
  • F.Hoffam La Roche
  • Teva Pharmaceuticals
  • Cipla
  • Fibrogen
  • Liminal Biosciences
  • PharmAkea Therapeutics
  • IQVIA
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Disease Type (USD MN)
  • Asthma Market Sales by Geography (USD MN)
  • Chronic Obstructive Pulmonary Disease (COPD) Market Sales by Geography (USD MN)
  • Lung Cancer Market Sales by Geography (USD MN)
  • Other Lung Disease Market Sales by Geography (USD MN)
  • Analysis Market by Drug Class (USD MN)
  • Corticosteroids Market Sales by Geography (USD MN)
  • Bronchodilator Medications Market Sales by Geography (USD MN)
  • Mucolytics Market Sales by Geography (USD MN)
  • Antimicrobial Medications Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Online Pharmacies Market Sales by Geography (USD MN)
  • Global Lung Disease Therapeutics Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Lung Disease Therapeutics Report
  • Market Research Process
  • Market Research Methodology
  • Global Lung Disease Therapeutics Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Disease Type
  • Market Attractiveness Analysis by Drug Class
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Disease Type (USD MN)
  • Asthma Market Sales by Geography (USD MN)
  • Chronic Obstructive Pulmonary Disease (COPD) Market Sales by Geography (USD MN)
  • Lung Cancer Market Sales by Geography (USD MN)
  • Other Lung Disease Market Sales by Geography (USD MN)
  • Global Market Analysis by Drug Class (USD MN)
  • Corticosteroids Market Sales by Geography (USD MN)
  • Bronchodilator Medications Market Sales by Geography (USD MN)
  • Mucolytics Market Sales by Geography (USD MN)
  • Antimicrobial Medications Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Online Pharmacies Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112112026

The global demand for Lung Disease Therapeutics Market is presumed to reach the market size of nearly USD 116.41 BN by 2030 from USD 80.41 BN in 2022 with a CAGR of 4.7% under the study period 2023 - 2030.

Lung disease therapeutics refers to the medical treatments and interventions aimed at managing and treating various lung-related disorders and diseases. It covers conditions affecting the respiratory system, including both acute and chronic diseases that impact lung function and overall respiratory health. These therapeutics can involve various approaches, including medications, therapies, changes in lifestyle, and, in some cases, surgical interventions.

MARKET DYNAMICS:

The increasing prevalence of lung diseases, driven by factors like pollution and ageing populations, fuels the demand for effective treatments. Environmental factors, technological advancements, and research contribute to the growing need for therapies. Personalized medicine and emerging biopharmaceuticals, such as targeted therapies, enhance treatment options. Rising healthcare expenditure, early diagnosis awareness, and stricter regulatory standards play significant roles. The COVID-19 pandemic highlighted respiratory health's importance and accelerated research in the field. Global initiatives, healthcare infrastructure development, and a patient-centric approach further influence the market. As patients and healthcare professionals seek improved therapies, the market is anticipated to evolve.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of lung disease therapeutics. The growth and trends of lung disease therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the lung disease therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Type

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Lung Cancer
  • Other Lung Disease

By Drug Class

  • Corticosteroids
  • Bronchodilator Medications
  • Mucolytics
  • Antimicrobial Medications
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Lung Disease Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Lung Disease Therapeutics market include GSK, AstraZeneca, Boehringer Ingelheim, Novartis, Mylan, Vertex Pharmaceuticals, F.Hoffam La Roche, Teva Pharmaceuticals, Cipla, Fibrogen, Liminal Biosciences, PharmAkea Therapeutics, IQVIA. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . LUNG DISEASE THERAPEUTICS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Disease Type
    • 3.7.2 Market Attractiveness Analysis By Drug Class
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL LUNG DISEASE THERAPEUTICS MARKET ANALYSIS BY DISEASE TYPE

  • 5.1 Overview by Disease Type
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Disease Type
  • 5.4 Asthma Historic and Forecast Sales by Regions
  • 5.5 Chronic Obstructive Pulmonary Disease (COPD) Historic and Forecast Sales by Regions
  • 5.6 Lung Cancer Historic and Forecast Sales by Regions
  • 5.7 Other Lung Disease Historic and Forecast Sales by Regions

6 . GLOBAL LUNG DISEASE THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS

  • 6.1 Overview by Drug Class
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Drug Class
  • 6.4 Corticosteroids Historic and Forecast Sales by Regions
  • 6.5 Bronchodilator Medications Historic and Forecast Sales by Regions
  • 6.6 Mucolytics Historic and Forecast Sales by Regions
  • 6.7 Antimicrobial Medications Historic and Forecast Sales by Regions
  • 6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL LUNG DISEASE THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1 Overview by Distribution Channel
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Distribution Channel
  • 7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
  • 7.5 Retail Pharmacies Historic and Forecast Sales by Regions
  • 7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL LUNG DISEASE THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE LUNG DISEASE THERAPEUTICS COMPANIES

  • 9.1. Lung Disease Therapeutics Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF LUNG DISEASE THERAPEUTICS INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. GSK
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. AstraZeneca
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Boehringer Ingelheim
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Novartis
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. Mylan
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Vertex Pharmaceuticals
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. F.Hoffam La Roche
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. Teva Pharmaceuticals
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. Cipla
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. Fibrogen
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments
  • 10.13. Liminal Biosciences
    • 10.13.1. Company Overview
    • 10.13.2. Company Revenue
    • 10.13.3. Products
    • 10.13.4. Recent Developments
  • 10.14. PharmAkea Therapeutics
    • 10.14.1. Company Overview
    • 10.14.2. Company Revenue
    • 10.14.3. Products
    • 10.14.4. Recent Developments
  • 10.15. IQVIA
    • 10.15.1. Company Overview
    • 10.15.2. Company Revenue
    • 10.15.3. Products
    • 10.15.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies